Thera-SAbDab

INOTUZUMAB

>   Structural Summary
TherapeuticInotuzumab
TargetCD22
Heavy ChainEVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS
Light ChainDVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG4
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2004
INN Year Recommended2005
Companies InvolvedAlliance for Clinical Trials in Oncology, Cancer Research UK, Case Comprehensive Cancer Center, Children's Oncology Group, Erasmus MC, M. D. Anderson Cancer Center, National Cancer Institute (USA), Pfizer, SWOG, University College London, University of Texas M. D. Anderson Cancer Center, Celltech Group
Conditions ApprovedPrecursor cell lymphoblastic leukaemia-lymphoma
Conditions ActivePrecursor B-cell lymphoblastic leukaemia-lymphoma, Chronic myeloid leukaemia
Conditions DiscontinuedAcute biphenotypic leukaemia, Burkitt's lymphoma, Diffuse large B cell lymphoma, Non-Hodgkin's lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]